Marijuana Internacional

"Germany’s landmark recreational cannabis law will go into effect on April 1 after clearing the final regulatory hurdle on Friday.

The Bundesrat, the upper house of the German Parliament, failed to reach a majority to convene the Mediation Committee, clearing the last potential delay to approval, ABC News reported.

The law, approved a month ago in the Bundestag by a 407-226 vote, generally
decriminalizes cannabis, allows for home grows and lays the legal framework for so-called “cultivation social clubs – nonprofit organizations where members can acquire marijuana for recreational use.

However, the law
stops short of establishing a regulated retail and distribution system for adult-use products, akin to more than 20 American states."

.
 
Werbung:
"Nearly sixty percent of people undergoing opioid maintenance treatment (OMT) use cannabis to reduce their cravings for other drugs, including heroin, according to survey data published in the journal European Archives of Psychiatry and Clinical Neuroscience.

German investigators assessed cannabis use trends in 118 subjects enrolled in OMT. Fifty-seven percent of respondents acknowledged consuming herbal cannabis,
despite its use being a violation of the program’s rules.

Nearly half (45 percent) of cannabis consumers said that they used it “to reduce cravings for heroin,” and 24 percent acknowledged doing so to reduce cravings for cocaine. Respondents also reported using
cannabis as a substitute for alcohol, benzodiazepines, and other controlled substances."

.
 
"Subjects who engage in the occasional use of cannabis, during their teens, exhibit no significant changes in cognitive functioning in young adulthood, according to longitudinal data published in the journal Psychopharmacology.

Portuguese researchers assessed reward-related brain activity, psychopathology, and cognitive functioning in a cohort of cannabis consumers and controls. Subjects in the study were all cannabis naïve at age 14. Investigators then conducted follow-up investigations when subjects were 19 and 22 years of age.

Researchers did not identify any significant cognitive differences at age 22 between occasional cannabis consumers and abstainers."

.
 
"Patients authorized to use medical cannabis products report decreasing their use of opioids, alcohol, tobacco, and other substances, according to a data analysis published in the journal Cannabis.

Investigators surveyed 2,697 Canadian medical cannabis registrants. The mean age of participants was 54.3 years of age.

Consistent with other surveys, respondents frequently reported substituting cannabis in lieu of other substances."

.
 
“While Euromonitor International estimates that 0.12% of the Japanese population are consumers who use illicit cannabis at least once a year, which shows a low figure compared to Western countries, Japan witnessed a surge in illegal cultivation and smuggling operations, particularly among younger generations. Despite the long-standing legal framework, the domestic illicit cannabis market in 2023 was estimated to be 2.5 times larger than the legal CBD market.

According to Euromonitor International, the
momentum for regulatory change in Japan gained traction due to the relaxation of cannabis regulations in other countries, prompting the Ministry of Health, Labour and Welfare to establish an expert panel to review the Cannabis Control Law in 2021.”
.
 
"Those who regularly consume cannabis do not exhibit so-called "amotivational syndrome,” even when they are acutely under the influence, according to data published in the journal Social Psychological and Personality Science.

Researchers affiliated with the University of Toronto assessed a cohort of 260 frequent cannabis consumers five times per day over a seven-day period. Investigators assessed subjects’ motivation and willingness to push themselves during times when they were under the influence and when they were not."
.
 
"The administration of a purified formulation of plant-derived CBD (aka Epidiolex) provides significant short-term relief to patients suffering from acute toothaches, according to placebo-controlled clinical trial data published in the journal Evidence-Based Dentistry."
.
 
"British researchers assessed the use of cannabis-based medicinal products (CBMPs) consisting of either flower or oil extracts in a cohort of osteoarthritis patients enrolled in the UK Medical Cannabis Registry. (Since 2018, British specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Researchers assessed changes in patient-reported outcomes measures over a one-year period.

Patients reported symptom improvements at one-month / three-months / six-months, and at one-year."
.
 
Werbung:
Back
Top